OPKO Completes Patient Recruitment in Second Phase 3 Trial of Rayaldy

OPKO Health OPK, has completed patient recruitment in the second phase 3 trial of RayaldyTM to treat patients with secondary hyperparathyroidism (SHPT), stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency. This trial is the second of two identical randomized, double-blind, placebo-controlled, multi-site studies intended to establish the safety and efficacy of RayaldyTM as a new treatment for SHPT in the targeted population. The endpoints of both studies, which are being conducted in parallel, include vitamin D status and changes in serum calcium, serum phosphorus and plasma intact parathyroid hormone (PTH). Each of the two pivotal phase 3 trials involves approximately 210 patients recruited at approximately 40 sites in the United States See full press release